Terms: = Ovarian cancer AND CD274, PDL1, 29126, ENSG00000120217, PDCD1L1, PD-L1, MGC142296, PDCD1LG1, MGC142294, B7H1, Q9NZQ7, B7-H AND Clinical Outcome
14 results:
1. A methylation- and immune-related lncRNA signature to predict ovarian cancer outcome and uncover mechanisms of chemoresistance.
Chen L; Gao W; Lin L; Sha C; Li T; Chen Q; Wei H; Yang M; Xing J; Zhang M; Zhao S; Xu W; Li Y; Long L; Zhu X
J Ovarian Res; 2023 Sep; 16(1):186. PubMed ID: 37674251
[TBL] [Abstract] [Full Text] [Related]
2. clinical outcome and Morphology-Based Analysis of p53 Aberrant and Mismatch Repair Protein-Deficient ovarian Clear Cell Carcinoma and Their Association With p16, HER2, and pd-l1 Expression.
Wilkins R; Lin LH; Xia R; Shiomi T; Zamuco RD; Shukla PS
Am J Clin Pathol; 2023 Nov; 160(5):466-476. PubMed ID: 37415414
[TBL] [Abstract] [Full Text] [Related]
3. Low plasma pd-l1 levels, early tumor onset and absence of peritoneal carcinomatosis improve prognosis of women with advanced high-grade serous ovarian cancer.
Fanale D; Brando C; Corsini LR; Cutaia S; Di Donna MC; Randazzo U; Filorizzo C; Lisanti C; Magrin L; Gurrera V; Romano R; Dimino A; Bazan Russo TD; Olive D; Vieni S; Pantuso G; Giordano A; Chiantera V; Russo A; Bazan V; Iovanna JL
BMC Cancer; 2023 May; 23(1):437. PubMed ID: 37179293
[TBL] [Abstract] [Full Text] [Related]
4. PTEN Deficiency in Tubo-ovarian High-Grade Serous Carcinoma is Associated with Poor Progression-Free Survival and is Mutually Exclusive with CCNE1 Amplification.
Zhang X; Wang A; Han L; Liang B; Allard G; Diver E; Howitt BE
Mod Pathol; 2023 May; 36(5):100106. PubMed ID: 36805789
[TBL] [Abstract] [Full Text] [Related]
5. cancer-associated fibroblasts-derived FMO2 as a biomarker of macrophage infiltration and prognosis in epithelial ovarian cancer.
Yu S; Yang R; Xu T; Li X; Wu S; Zhang J
Gynecol Oncol; 2022 Nov; 167(2):342-353. PubMed ID: 36114029
[TBL] [Abstract] [Full Text] [Related]
6. Construction of an Immune Cell Infiltration Score to Evaluate the Prognosis and Therapeutic Efficacy of ovarian cancer Patients.
Liu J; Wang Y; Yuan S; Wei J; Bai J
Front Immunol; 2021; 12():751594. PubMed ID: 34745124
[TBL] [Abstract] [Full Text] [Related]
7. Application of Immunoprofiling Using Multiplexed Immunofluorescence Staining Identifies the Prognosis of Patients with High-Grade Serous ovarian cancer.
Lee SW; Lee HY; Kang SW; Kim MJ; Lee YJ; Sung CO; Kim YM
Int J Mol Sci; 2021 Sep; 22(17):. PubMed ID: 34502561
[TBL] [Abstract] [Full Text] [Related]
8. Identification of biomarkers complementary to homologous recombination deficiency for improving the clinical outcome of ovarian serous cystadenocarcinoma.
Shi Z; Zhao Q; Lv B; Qu X; Han X; Wang H; Qiu J; Hua K
Clin Transl Med; 2021 May; 11(5):e399. PubMed ID: 34047476
[TBL] [Abstract] [Full Text] [Related]
9. PD-1 and pd-l1 expression on TILs in peritoneal metastases compared to ovarian tumor tissues and its associations with clinical outcome.
Bekos C; Pils D; Dekan S; Hofstetter G; Horak P; Reinthaller A; Polterauer S; Schwameis R; Aust S
Sci Rep; 2021 Mar; 11(1):6400. PubMed ID: 33737722
[TBL] [Abstract] [Full Text] [Related]
10. Combined pembrolizumab and pegylated liposomal doxorubicin in platinum resistant ovarian cancer: A phase 2 clinical trial.
Lee EK; Xiong N; Cheng SC; Barry WT; Penson RT; Konstantinopoulos PA; Hoffman MA; Horowitz N; Dizon DS; Stover EH; Wright AA; Campos SM; Krasner C; Morrissey S; Whalen C; Quinn R; Matulonis UA; Liu JF
Gynecol Oncol; 2020 Oct; 159(1):72-78. PubMed ID: 32771276
[TBL] [Abstract] [Full Text] [Related]
11. High RIG-I expression in ovarian cancer associates with an immune-escape signature and poor clinical outcome.
Wolf D; Fiegl H; Zeimet AG; Wieser V; Marth C; Sprung S; Sopper S; Hartmann G; Reimer D; Boesch M
Int J Cancer; 2020 Apr; 146(7):2007-2018. PubMed ID: 31800094
[TBL] [Abstract] [Full Text] [Related]
12. Adenocarcinoma of the uterine cervix: Pathologic features, treatment options, clinical outcome and prognostic variables.
Gadducci A; Guerrieri ME; Cosio S
Crit Rev Oncol Hematol; 2019 Mar; 135():103-114. PubMed ID: 30819439
[TBL] [Abstract] [Full Text] [Related]
13. Immune Checkpoint Inhibitors in Gynecological cancers: Update of Literature and Perspectives of clinical Research.
Gadducci A; Guerrieri ME
Anticancer Res; 2017 Nov; 37(11):5955-5965. PubMed ID: 29061774
[TBL] [Abstract] [Full Text] [Related]
14. Anti-pd-l1/PD-1 immune therapies in ovarian cancer: basic mechanism and future clinical application.
Mandai M; Hamanishi J; Abiko K; Matsumura N; Baba T; Konishi I
Int J Clin Oncol; 2016 Jun; 21(3):456-61. PubMed ID: 26968587
[TBL] [Abstract] [Full Text] [Related]
